

## **Supplementary Information**

### **Influence of genetic variants in EGF and other genes on hematological traits in Korean populations by a genome-wide approach**

Yun Kyoung Kim<sup>1\*</sup>, Ji Hee Oh<sup>1\*</sup>, Young Jin Kim<sup>1</sup>, Mi Yeong Hwang<sup>1</sup>, Sanghoon Moon<sup>1</sup>, Siew-Kee Low<sup>2</sup>, Atsushi Takahashi<sup>2</sup>, Koichi Matsuda<sup>3</sup>, Michiaki Kubo<sup>2</sup>, Juyoung Lee<sup>1</sup> and Bong-Jo Kim<sup>1§</sup>

<sup>1</sup>*Division of Structural and Functional Genomics, Center for Genome Science, National Institute of Health, Centers for Disease Control and Prevention, Chungcheongbuk-do, Korea,*

<sup>2</sup>*Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan,* <sup>3</sup>*Institute of Medical Science, The University of Tokyo, Tokyo, Japan*


\*These authors contributed equally to this work.

<sup>§</sup>Corresponding author:


Bong-Jo Kim, Ph.D.

Division of Structural and Functional Genomics, Center for Genome Science, National Institute of Health, Centers for Disease Control and Prevention, Chungcheongbuk-do, Korea, 361-951, Phone : +82-43-719-8870, FAX : +82-43-719-8908, E-mail : kbj6181@cdc.go.kr

**Supplementary Figure 1** The quantile - quantile plots for five hematological traits in discovery stage showed genome-wide distribution of the empirically observed of test statistic in comparison with the expected null distribution. (a) is plots for Hb, (b) is for Hct, (c) is for RBC, (d) is for WBC and (e) is for PLT.



Platelet



**Supplementary Figure 2** Population diversity of rs2282786 referring from Database of Single Nucleotide Polymorphism (dbSNP, <http://www.ncbi.nlm.nih.gov/snp/>)

Population	Sample Ascertainment			Genotype Detail			Alleles		
	Individual Group	Chrom. Sample Cnt.	Source	C/C	C/T	T/T	HWP	C	
<a href="#">AFD_EUR_PANEL</a>	European	48	IG				1.000		1.000
<a href="#">AFD_AFR_PANEL</a>	African American	46	IG				1.000		1.000
<a href="#">AFD_CHN_PANEL</a>	Asian	46	IG	0.087	0.652	0.261	0.1000	0.413	0.587
<a href="#">HapMap-CEU</a>	European	120	IG				1.000		1.000
<a href="#">HapMap-HCB</a>	Asian	90	IG	0.089	0.356	0.556	0.584	0.267	0.733
<a href="#">HapMap-JPT</a>	Asian	86	IG	0.070	0.326	0.605	0.584	0.233	0.767
<a href="#">HapMap-YRI</a>	Sub-Saharan African	118	IG				1.000		1.000
<a href="#">pilot_1_CHB+JPT_low_coverage_panel</a>		120	AF					0.258	0.742
<a href="#">JBIC-allele</a>		728	AF					0.211	0.789

**Supplementary Table 1. Descriptive statistics of samples analyzed in this study**

Traits	Discovery		Replication 1		Replication 2		Replication 3	
	KARE (n=8,842)		CAVAS (n=3,667)		Health2 (n=8,053)		BioBank Japan (n=23,032)	
Age	52.2 ± 8.92		59.8 ± 10.05		56.8 ± 7.85		63.5 ± 11.94	
Sex	male (%)	4,183 (47.3%)		1,375 (37.5%)		3,281 (40.7%)		12,366 (53.7%)
	female (%)	4,659 (52.7%)		2,292 (62.5%)		4,762 (59.1%)		10,666 (46.3%)
Hemoglobin (g/dL)	13.6 ± 1.60	11.8	13.6 ± 1.43	10.5	-	-	-	-
Hematocrit (%)	41.0 ± 4.60	11.2	40.4 ± 4.15	10.3	-	-	-	-
RBC ( $\times 10^6/\mu\text{L}$ )	4.42 ± 0.49	11.1	4.34 ± 0.42	9.7	-	-	-	-
WBC ( $\times 10^3/\mu\text{L}$ )	6.59 ± 1.84	27.9	6.57 ± 1.87	28.5	-	-	-	-
Platelet count ( $\times 10^3/\mu\text{L}$ )	266.3 ± 65.3	24.5	258.6 ± 62.0	24.0	258.0 ± 62.4	24.2	231.1 ± 90.9	39.3

n, sample size; RBC, red blood cell count; WBC, white blood cell count; CV, coefficient of variation;

KARE, Korean Association Resource Project; CAVAS, Cardiovascular disease Association Study;

Data are shown as mean ± standard deviation.

**Supplementary Table 2. Genomic inflation factors of analyses in the discovery stage**

Trait	Inflation factor
Hb	1.003623
Hct	1.016721
RBC	1.035321
WBC	1.029904
PLT	1.036225

Genomic inflation factor is defined as the ratio of the median of the observed distribution of the test statistic to the expected median.

**Supplementary Table 3. Association results of 32 variants that were verified in the replication stage.**

Trait	CHR	SNP	Cytoband	BP	Gene	A1/A2	MAF	Discovery (KARE, n=8,842)		Replication (CAVAS, n=3,667)		Combined (n=12,509)		
								effect size	P	effect size	P	effect size	P	P <sub>het</sub> (Q)
Hb	22	rs2076086	22q12.3	35800482	TMPRSS6	T/C	0.49	0.09 ± 0.02	7.33E-07	0.11 ± 0.03	3.24E-05	0.09 ± 0.01	1.19E-10	0.52(0.41)
	2	rs2218660	2p21	46201296	PRKCE	G/T	0.18	-0.09 ± 0.02	6.51E-05	-0.09 ± 0.03	6.04E-03	-0.09 ± 0.02	1.25E-06	0.95(0.00)
	6	rs2523554	6p21.33	31439808	HLA-B-MICA	C/T	0.12	0.11 ± 0.03	9.34E-05	0.10 ± 0.04	1.44E-02	0.11 ± 0.02	4.06E-06	0.87(0.03)
Hct	6	rs9376090	6q23.3	135452921	HBS1L-MYB	C/T	0.32	-0.35 ± 0.05	1.68E-10	-0.18 ± 0.08	2.68E-02	-0.30 ± 0.05	6.20E-11	0.08(3.05)
	2	rs2218660	2p21	46201296	PRKCE	G/T	0.18	-0.30 ± 0.07	4.69E-06	-0.27 ± 0.10	5.84E-03	-0.29 ± 0.05	9.22E-08	0.81(0.06)
RBC	6	rs7775698	6q23.3	135460328	HBS1L-MYB	T/C	0.33	-0.07 ± 0.01	6.82E-34	-0.06 ± 0.01	4.92E-12	-0.07 ± 0.01	2.69E-44	0.20(1.68)
	4	rs17084406	4q12	55056941	PDGFRA-KIT	G/A	0.26	-0.04 ± 0.01	2.09E-11	-0.05 ± 0.01	1.81E-08	-0.05 ± 0.01	2.85E-18	0.36(0.85)
	6	rs3218108	6p21.1	42010633	CCND3	T/C	0.22	0.04 ± 0.01	2.15E-10	0.05 ± 0.01	2.54E-06	0.04 ± 0.01	2.59E-15	0.79(0.07)
	12	rs7138216	12p13.32	4204569	PARP11-CCND2	C/G	0.27	-0.03 ± 0.01	2.70E-07	-0.03 ± 0.01	4.73E-03	-0.03 ± 0.01	5.19E-09	0.54(0.37)
	9	rs8176743	9q34.2	135121236	ABO	T/C	0.21	0.03 ± 0.01	9.88E-07	0.03 ± 0.01	5.73E-03	0.03 ± 0.01	2.12E-08	0.62(0.25)
	2	rs2218660	2p21	46201296	PRKCE	G/T	0.18	-0.03 ± 0.01	2.90E-06	-0.03 ± 0.01	2.90E-03	-0.03 ± 0.01	2.94E-08	0.85(0.04)
	6	rs11153167	6q21	109729275	CCDC162P	T/A	0.11	-0.04 ± 0.01	5.10E-05	-0.03 ± 0.01	3.72E-02	-0.03 ± 0.01	6.12E-06	0.57(0.33)
	8	rs16887645	8q23.3	116767229	TRPS1-LINC00536	A/C	0.08	-0.04 ± 0.01	7.00E-05	-0.04 ± 0.02	2.13E-02	-0.04 ± 0.01	4.49E-06	0.75(0.10)
	16	rs11859733	16q21	56889274	PRSS54-GINS3	C/T	0.26	-0.03 ± 0.01	8.56E-05	-0.03 ± 0.01	3.62E-03	-0.03 ± 0.01	1.01E-06	0.96(0.00)
	17	rs8070454	17q21.1	35414280	PSMD3-CSF3	T/C	0.47	0.16 ± 0.03	3.62E-09	0.11 ± 0.04	8.68E-03	0.15 ± 0.02	1.74E-10	0.31(1.04)
WBC	3	rs10936603	3q26.2	171028346	LRRIQ4	G/T	0.32	-0.14 ± 0.03	4.42E-06	-0.09 ± 0.05	4.36E-02	-0.12 ± 0.02	7.40E-07	0.41(0.68)
	7	rs11981340	7q21.2	92153596	CDK6	C/T	0.34	-0.13 ± 0.03	4.99E-06	-0.20 ± 0.04	9.58E-06	-0.15 ± 0.02	4.33E-10	0.21(1.58)
	2	rs3729569	2q21.3	136319775	MCM6	T/G	0.18	0.15 ± 0.04	6.87E-05	0.16 ± 0.06	3.59E-03	0.15 ± 0.03	8.33E-07	0.79(0.07)
	4	rs9760319	4q28.3	138631979	NONE-PCDH18	G/A	0.43	0.11 ± 0.03	9.17E-05	0.09 ± 0.04	3.94E-02	0.10 ± 0.02	1.04E-05	0.73(0.12)
PLT	4	rs2282786	4q25	111141945	EGF	C/T	0.25	-6.66 ± 1.12	3.18E-09	-6.58 ± 1.74	1.58E-04	-6.64 ± 0.94	2.05E-12	0.97(0.00)
	22	rs1977081	22q13.31	42661461	PNPLA3	C/T	0.41	-5.84 ± 1.00	4.70E-09	-3.76 ± 1.61	1.94E-02	-5.27 ± 0.85	5.10E-10	0.27(1.21)
	12	rs739496	12q24.12	110372042	SH2B3	A/G	0.11	-8.36 ± 1.57	1.06E-07	-5.75 ± 2.39	1.60E-02	-7.57 ± 1.31	8.00E-09	0.36(0.84)

6	rs9277053	6p21.32	33114200	HLA-DOA-HLA-DPA1	A/G	0.34	5.18 ± 1.05	7.95E-07	5.27 ± 1.62	1.18E-03	5.21 ± 0.88	3.43E-09	0.96(0.00)
6	rs9399137	6q23.3	135460711	HBS1L-MYB	C/T	0.33	5.24 ± 1.07	1.06E-06	5.00 ± 1.63	2.20E-03	5.17 ± 0.90	8.07E-09	0.90(0.02)
3	rs13091574	3q27.1	185574799	THPO	C/A	0.16	6.39 ± 1.32	1.28E-06	6.22 ± 2.14	3.73E-03	6.34 ± 1.12	1.62E-08	0.94(0.01)
6	rs9469032	6p21.33	31753405	LY6G5C	G/C	0.03	12.7 ± 2.76	4.42E-06	16.6 ± 4.34	1.35E-04	13.8 ± 2.33	3.12E-09	0.45(0.58)
6	rs5745582	6p21.31	33654476	BAK1	T/C	0.22	5.03 ± 1.16	1.52E-05	5.39 ± 1.81	2.88E-03	5.14 ± 0.98	1.48E-07	0.87(0.03)
11	rs7946919	11q23.3	118646042	CBL	G/A	0.44	4.42 ± 1.03	1.83E-05	4.84 ± 1.56	1.92E-03	4.55 ± 0.86	1.23E-07	0.82(0.05)
13	rs4519241	13q31.1	84301372	MIR548F1-SLITRK6	C/A	0.40	-4.18 ± 1.01	3.26E-05	-3.82 ± 1.60	1.70E-02	-4.08 ± 0.85	1.67E-06	0.85(0.04)
22	rs2266950	22q11.21	19566372	SNAP29	A/G	0.05	9.57 ± 2.32	3.61E-05	7.14 ± 3.60	4.71E-02	8.86 ± 1.95	5.36E-06	0.57(0.32)
7	rs10260466	7p12.1	53688906	POM121L12-FLJ45974	A/C	0.22	-4.69 ± 1.18	7.11E-05	-4.36 ± 1.83	1.71E-02	-4.59 ± 0.99	3.60E-06	0.88(0.02)
17	rs6065	17p13.2	4777161	GP1BA	T/C	0.09	6.81 ± 1.74	8.82E-05	8.89 ± 2.58	5.78E-04	7.46 ± 1.44	2.25E-07	0.50(0.45)

A1 is defined as minor allele and A2 is major allele.

**Supplementary Table 4. Replication of previously reported loci associated with hematological traits in Korean populations (SNP ID perfectly matched).**

Trait	SNP	CHR	BP	Gene	A1/A2	Previously implicated				Replicated in Korean population (n=8,842)	
						MAF	effect size	P	Reference	effect size	P
Hb	rs10495928	2	46206670	PRKCE	G/A	0.34	0.06 ± 0.009	$7.05 \times 10^{-13}$	[1]	-0.07 ± 0.023	1.17E-03
	rs495828	9	135144688	ABO	T/G	0.28	-0.09 ± 0.013	$1.18 \times 10^{-11}$	[2]	-0.08 ± 0.020	2.26E-05
	rs6013509	20	50751758	TSHZ2	A/G	0.18	-0.06 ± 0.010	$1.05 \times 10^{-10}$	[1]	-0.02 ± 0.019	0.2118
	rs5756504	22	35797216	TMPRSS6	T/C	0.45	0.08 ± 0.012	$1.64 \times 10^{-10}$	[2]	0.09 ± 0.017	8.65E-07
Hct	rs10168349	2	46208555	PRKCE	C/G	0.34	0.19 ± 0.024	$3.75 \times 10^{-15}$	[1]	-0.26 ± 0.065	6.26E-05
	rs7775698	6	135460328	HBS1L-MYB	T/C	0.35	-0.08 ± 0.012	$9.52 \times 10^{-11}$	[2]	-0.35 ± 0.055	2.10E-10
	rs7385804	7	100073906	TFR2	C/A	0.38	-0.15 ± 0.024	$4.45 \times 10^{-10}$	[1]	0.06 ± 0.086	0.5114
	rs495828	9	135144688	ABO	T/G	0.28	-0.08 ± 0.013	$6.06 \times 10^{-10}$	[2]	-0.22 ± 0.057	9.26E-05
RBC	rs2413450	22	35800170	TMPRSS6	T/C	0.38	-0.17 ± 0.024	$1.85 \times 10^{-13}$	[1]	0.19 ± 0.050	1.42E-04
	rs10495928	2	46206670	PRKCE	G/A	0.17	-0.09 ± 0.016	$3.81 \times 10^{-08}$	[2]	-0.03 ± 0.007	1.11E-04
	rs3218097	6	42013253	USP49-MED20-BYSL-CCND3	T/C	0.19	0.10 ± 0.015	$1.09 \times 10^{-10}$	[2]	0.04 ± 0.007	2.69E-10
	rs11966072	6	109741521	C6orf182-CD164	G/A	0.10	-0.11 ± 0.020	$6.92 \times 10^{-09}$	[2]	-0.03 ± 0.009	1.98E-04
WBC	rs7775698	6	135460328	HBS1L-MYB	T/C	0.35	-0.18 ± 0.012	$7.31 \times 10^{-48}$	[2]	-0.07 ± 0.006	6.82E-34
	rs495828	9	135144688	ABO	T/G	0.28	-0.09 ± 0.013	$3.33 \times 10^{-12}$	[2]	-0.03 ± 0.006	1.21E-06
	rs11611647	12	4204180	CCND2	C/T	0.37	-0.07 ± 0.012	$6.44 \times 10^{-09}$	[2]	-0.03 ± 0.006	3.15E-07
	rs3094212	6	31193749	CDSN-PSORS1C1	C/T	0.35	0.07 ± 0.012	$6.76 \times 10^{-09}$	[2]	0.07 ± 0.029	1.25E-02
PLT	rs4895441	6	135468266	HBS1L-MYB	G/A	0.37	-0.07 ± 0.012	$1.67 \times 10^{-09}$	[2]	-0.12 ± 0.029	1.26E-05
	rs4065321	17	35397074	GSDMA-PSMD3-CSF3-MED24	T/C	0.32	-0.09 ± 0.012	$2.94 \times 10^{-14}$	[2]	-0.16 ± 0.028	1.45E-08
	rs5745568	6	33656372	BAK1	T/G	0.23	0.09 ± 0.014	$6.66 \times 10^{-11}$	[2]	5.00 ± 1.163	1.72E-05
	rs7775698	6	135460328	HBS1L-MYB	T/C	0.34	0.09 ± 0.012	$2.54 \times 10^{-14}$	[2]	5.28 ± 1.071	8.49E-07

rs739496	12	110372042	SH2B3	A/G	0.16	-0.14 ± 0.016	$4.75 \times 10^{-19}$	[2]	-8.36 ± 1.572	1.06E-07
----------	----	-----------	-------	-----	------	---------------	------------------------	-----	---------------	----------

A1 is defined as minor allele and A2 is major allele. [1], Ganesh *et al.* 2009; [2], Kamatani *et al.* 2010;